Skip to content

To evaluate the characteristic changes of sevoflurane, propofol and esketamine induced unconscious EEG in diabetes patients and non-diabetes patients

To evaluate the characteristic changes of sevoflurane, propofol and esketamine induced unconscious EEG in diabetes patients and non-diabetes patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075108
Enrollment
Unknown
Registered
2023-08-25
Start date
2023-08-25
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Group esketamine(Healthy patients):esketamine anesthesia induction
Group L-Sevoflurane(T2DM patients):Sevoflurane anesthesia induction
Group L-Sevoflurane(Healthy patients):Sevoflurane anesthesia induction
Group Propofol(T2DM patients):Propofol anesthesia induction
Group Propofol(Healthy patients):Propofol anesthesia induction
Group H-Sevoflurane(T2DM patients):Sevoflurane anesthesia induction
Group H-Sevoflurane(Healthy patients):Sevoflurane anesthesia induction
Group esketamine(T2DM patients):esketamine anesthesia induction

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-60 years old, ASA I-III grade, surgical patient under general anesthesia; (2) Previously healthy patients (glycated hemoglobin<5.7%, fasting blood glucose<6.1 mmol/L) or simply diagnosed as T2DM patients; (3) Smooth communication, willing to participate in this study, and willing to provide informed consent.

Exclusion criteria

Exclusion criteria: (1) ASA = Level III patients with severe illnesses, including indigestion, liver failure, renal failure, severe gallbladder and pancreatic diseases, stroke, malignant tumors, or unstable cardiovascular diseases (such as myocardial infarction, ketosis, or hyperthyroidism); (2) Patients taking glucocorticoids; And patients with fasting blood glucose>10 mmol/L, random or postprandial blood glucose = 12 mmol/L, or glycated hemoglobin>9% during the intervention period; (3) Serious visual and auditory barriers, language barriers, and/or communication difficulties that result in inability to communicate; (4) Patients with concomitant neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, psychological disorders, alcohol dependence, and drug addiction; (5) Those who have used sedative drugs within a week, or those who have previously used sedative drugs for a long period of time (= 3 months); (6) Individuals with mental illness; (7) Preoperative cognitive impairment with MMSE scores lower than the corresponding educational threshold: illiteracy = 17 points, primary school (education = 6 years) = 20 points, secondary school or above (education>6 years) = 23 points; (8) The surgical time is less than 30 minutes, and the stable period of anesthesia cannot be identified; (9) Accidental discharge or refusal to participate in this study.

Design outcomes

Primary

MeasureTime frame
The time of consciousness disappearance, postoperative agitation and postoperative pain scores of different anesthetics in healthy patients and diabetes patients were observed.;

Secondary

MeasureTime frame
To observe the changes of EEG (including EEG power, amplitude phase coupling, brain network analysis related indicators), analgesic drug use and blood biochemical indicators between non diabetes patients and diabetes patients with different anesthetics;;To observe the effect of different anesthetics on the dreams of non diabetes patients and diabetes patients;

Countries

China

Contacts

Public ContactBin Han

Peking University Third Hospital

1711110326@pku.edu.cn+86 136 0107 6527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026